reslizumab (Rx)

Brand and Other Names:Cinqair
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

IV solution

  • 100mg/10mL vial (10mg/mL)

Asthma

Add-on maintenance treatment of patients with an eosinophilic phenotype

Severe asthma: 3 mg/kg IV q4wk infused over 20-50 minutes

Dosing Considerations

Limitations of use: Not indicated for treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus

Safety and efficacy not established

Next:

Adverse Effects

>10%

Elevated CPK, transient (20%)

1-10%

Treatment-emergent antibody response (5.4%)

Oropharyngeal pain (2.6%)

Musculoskeletal (2.2%)

Myalgias (1%)

<1%

Elevated CPK >10x ULN (0.8%)

Malignancy (0.6%)

Anaphylaxis (0.3%)

Previous
Next:

Warnings

Black Box Warnings

Anaphylaxis occurred in 0.3% of patients in placebo-controlled studies

Manifestations included dyspnea, decreased oxygen saturation, wheezing, vomiting, and skin and mucosal involvement, including urticaria

Observe patients for an appropriate period after infusion; healthcare professionals should be prepared to manage anaphylaxis that can be life-threatening

Discontinue immediately if the patient experiences anaphylaxis

Contraindications

Known hypersensitivity to reslizumab or its excipients

Cautions

Anaphylaxis reported observed during or within 20 minutes after completion of the IV infusion and reported as early as the second dose (see Black Box Warnings)

Not for use to treat acute asthma symptoms or acute exacerbations

No clinical studies have been conducted to assess reduction of maintenance corticosteroid dosages following administration of reslizumab; do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of reslizumab therapy

Diverse malignancies observed with reslizumab vs placebo in clinical trials (0.6% vs 0.3%)

Treat patients with pre-existing helminth infections before initiating reslizumab; if patients become infected during reslizumab treatment and do not respond to antihelminth treatment, discontinue reslizumab until infection resolves

Previous
Next:

Pregnancy

Pregnancy

Data are insufficient regarding drug-associated risk during pregnancy

Monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters of pregnancy

Reslizumab has a long half-life; this should be taken into consideration

Clinical considerations

  • Increased risk of preeclampsia in women with poorly or moderately controlled asthma
  • Prematurity, low birth weight, and small for gestational age observed in neonates whose mothers have poor or moderate asthma control
  • Asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control

Animal studies

  • Not teratogenic in mice or rabbits; data based on 2 single-dose studies in pregnant mice and rabbits during organogenesis 0.4, 1.5, and 6 times the exposures achieved at the maximum recommended human dose (MRHD) in mice on an AUC basis and 0.67, 3.3, and 17 times the exposures achieved at the MRHD in rabbits on a mg/kg basis

Lactation

Unknown if distributed in human breast milk; however, human IgG is known to be present in human milk

Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Interleukin-5 (IL-5) antagonist monoclonal antibody (IgG kappa); binds to IL-5, thereby inhibiting IL-5 bioactivity by blocking its binding to IL-5 alpha receptor complex expressed on the eosinophil surface

IL-5 is the major cytokine responsible for eosinophil growth and differentiation, recruitment, activation, and survival

Inflammation is an important component of asthma pathogenesis

Multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation

In patients with asthma, the eosinophilic phenotype is associated with compromised lung function, more frequent symptoms, and increased risk of exacerbations

Absorption

Peak plasma concentration: Observed at end of IV infusion

Distribution

Vd: 5 L

Metabolism

Similar to other monoclonal antibodies, reslizumab is degraded by enzymatic proteolysis into small peptides and amino acids

Elimination

Half-life: 24 days

Clearance: 7 mL/hr

Previous
Next:

Administration

IV Preparation

Remove from refrigerator

To minimize foaming, do not shake

Inspect visually for particulate matter and discoloration prior to administration; solution should appear clear to slightly hazy/opalescent, colorless to slightly yellow liquid

Since reslizumab is a protein, proteinaceous particles may be present in the solution that appear as translucent to white, amorphous particulates

Do not administer if discolored or if other foreign particulate matter is present

Withdraw proper volume from the vial(s) based on recommended weight-based dosage; discard any unused portion

Dispense syringe contents slowly to minimize foaming into a 50-mL 0.9% NaCl infusion bag

Compatible with polyvinylchloride (PVC) or polyolefin infusion bags

Gently invert bag to mix solution; do not shake

Do not mix or dilute with other drugs

Administer immediately after preparation; if not used immediately, refrigerate diluted solution at 2-8°C (36-46°F) or at room temperature up to 25ºC (77ºF), protected from light, for up to 16 hr

The time between preparation and administration should not exceed 16 hr

IV Administration

For IV infusion only following further dilution; do not administer as IV push or bolus

Administer in a healthcare setting by a healthcare professional prepared to manage anaphylaxis

If refrigerated before administration, allow diluted solution to reach room temperature

Use an infusion set with in-line, low protein-binding filter (pore size of 0.2-micron)

Compatible with polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate in-line infusion filters

Infuse diluted solution IV over 20-50 minutes; infusion time may vary depending on the total volume to be infused as based on patient weight

Do not infuse concomitantly in the same IV line with other agents; no physical or biochemical compatibility studies conducted

Monitor for hypersensitivity during the infusion and for an appropriate period afterwards

Upon infusion completion, flush IV line with 0.9% NaCl to ensure that entire reslizumab dose has been administered

Storage

Unopened vials

  • Refrigerate at 2-8ºC (36-46°F)
  • Do not freeze
  • Do not shake
  • Protect the vials from light by storing in the original package until time of use

Diluted solution

  • If not used immediately, refrigerate at 2-8°C (36-46°F) or at room temperature up to 25ºC (77ºF), protected from light, for up to 16 hr
  • Time between preparation and administration should not exceed 16 hr
  • Do not shake
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.